| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics, Inc. | EVP, General Counsel | Common Stock | 81.6K | $2.69M | $32.99 | Mar 4, 2024 | Direct |
| Intellia Therapeutics, Inc. | EVP, General Counsel | Stock Option (right to buy) | 46.8K | Mar 1, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | Mar 1, 2024 | 3 | -$75.8K | 4 | Mar 5, 2024 | EVP, General Counsel |
| NTLA | Intellia Therapeutics, Inc. | Jan 3, 2024 | 1 | -$112K | 4 | Jan 5, 2024 | EVP, General Counsel |
| NTLA | Intellia Therapeutics, Inc. | Mar 1, 2023 | 4 | -$47.7K | 4 | Mar 3, 2023 | EVP, General Counsel |
| NTLA | Intellia Therapeutics, Inc. | Jan 4, 2023 | 1 | -$42.3K | 4 | Jan 6, 2023 | EVP, General Counsel |
| NTLA | Intellia Therapeutics, Inc. | Mar 1, 2022 | 1 | $0 | 4/A | Mar 4, 2022 | EVP, General Counsel |
| NTLA | Intellia Therapeutics, Inc. | Jul 1, 2021 | 1 | $0 | 4 | Jul 6, 2021 | EVP, General Counsel |
| NTLA | Intellia Therapeutics, Inc. | Jun 23, 2021 | 0 | $0 | 3 | Jul 6, 2021 | EVP, General Counsel |